Get the Stockscreener App
2.09
4.13%
-0.09
After Hours:
2.11
0.02
+0.96%
Vor Biopharma Inc stock is traded at $2.09, with a volume of 1.71M.
It is down -4.13% in the last 24 hours and up +9.42% over the past month.
Vor Biopharma Inc is a clinical stage cell therapy company. It combines a novel patient engineering approach with targeted therapies to provide a solution for patients suffering from hematological malignancies. The company's products include VCAR33, Tremcel and Myelodysplastic Syndrome, Trem-cel+VCAR33 Treatment System, VADC45, CD123, CLL1, EMR2.
See More
Previous Close:
$2.18
Open:
$2.16
24h Volume:
1.71M
Relative Volume:
0.10
Market Cap:
$264.67M
Revenue:
-
Net Income/Loss:
$-112.46M
P/E Ratio:
-1.2744
EPS:
-1.64
Net Cash Flow:
$-99.89M
1W Performance:
-5.43%
1M Performance:
+9.42%
6M Performance:
+39.33%
1Y Performance:
+140.23%
1-Day Range:
$2.05
$2.20
1-Week Range:
$1.98
$2.3789
52-Week Range:
$0.1311
$3.29
Vor Biopharma Inc Stock (VOR) Company Profile
Name
Vor Biopharma Inc
Sector
Industry
Phone
617-655-6580
Address
100 CAMBRIDGEPARK DRIVE, CAMBRIDGE
Compare VOR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VOR
Vor Biopharma Inc
|
2.09 | 272.41M | 0 | -112.46M | -99.89M | -1.64 |
|
VRTX
Vertex Pharmaceuticals Inc
|
385.65 | 96.11B | 11.42B | 3.64B | -1.26B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
555.13 | 60.40B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
428.14 | 54.91B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
673.15 | 41.30B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
298.52 | 33.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Vor Biopharma Inc Stock (VOR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-30-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Jul-26-22 | Initiated | Wedbush | Outperform |
| Apr-27-22 | Initiated | Goldman | Neutral |
| Dec-17-21 | Initiated | H.C. Wainwright | Buy |
| Dec-03-21 | Initiated | Robert W. Baird | Outperform |
| Dec-02-21 | Initiated | Oppenheimer | Outperform |
| Oct-19-21 | Initiated | JMP Securities | Mkt Outperform |
| Mar-25-21 | Initiated | B. Riley Securities | Buy |
| Mar-03-21 | Initiated | Barclays | Overweight |
| Mar-03-21 | Initiated | Evercore ISI | Outperform |
| Mar-02-21 | Initiated | Goldman | Sell |
| Mar-02-21 | Initiated | Stifel | Buy |
View All
Vor Biopharma Inc Stock (VOR) Latest News
Intraday Charts Show Spike in Vor Biopharma Inc. ActivitySwing Trade Plans Emphasize Risk Management - metal.it
Vor Bio Appoints Seasoned Biotech Executive Dallan Murray as Chief Commercial Officer - GlobeNewswire
What are Vor Biopharma Inc. company’s key revenue driversDynamic investment opportunities - Jammu Links News
How volatile is Vor Biopharma Inc. stock compared to the marketBuild a portfolio with strong long-term growth - Jammu Links News
What institutional investors are buying Vor Biopharma Inc. stockAchieve breakthrough investment performance - Jammu Links News
Why is Vor Biopharma Inc. stock attracting strong analyst attentionBuild wealth faster with expert stock picks - Jammu Links News
What catalysts could drive Vor Biopharma Inc. stock higher in 2025Navigate market volatility with smart strategies - Jammu Links News
What drives Vor Biopharma Inc. stock priceInvest smarter with expert trading signals - Jammu Links News
How does Vor Biopharma Inc. generate profit in a changing economyHigh-impact stock picks - Jammu Links News
What analysts say about Vor Biopharma Inc. stockRapid-fire capital growth - Jammu Links News
What makes Vor Biopharma Inc. stock price move sharplyCapitalize on market momentum for maximum gains - Jammu Links News
Is Vor Biopharma Inc. stock overvalued or undervaluedSignificant capital appreciation - Jammu Links News
How many analysts rate Vor Biopharma Inc. as a “Buy”Capitalize on fast-moving trading opportunities - Jammu Links News
What are the technical indicators suggesting about Vor Biopharma Inc.Rapid wealth creation - Jammu Links News
Vor Biopharma Inc. (NASDAQ:VOR) Sees Large Growth in Short Interest - MarketBeat
VOR SEC FilingsVor Biopharma Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Why Vor Biopharma Inc. stock attracts strong analyst attentionSwing Trading Plan With Smart Signals in Review - metal.it
Insiders the biggest winners as Vor Biopharma Inc.'s (NASDAQ:VOR) market cap rises to US$302m - simplywall.st
When is Vor Biopharma Inc. stock expected to show significant growth - jammulinksnews.com
Vor Biopharma (VOR) Jumps 10% on Addition of 2 CEOs to Board - MSN
These 10 Stocks are Winning Big - Insider Monkey
Vor Biopharma Shares Soar After Strategic Appointments in Leadership - StocksToTrade
Published on: 2025-07-28 13:58:09 - metal.it
What are analysts’ price targets for Vor Biopharma Inc. in the next 12 monthsGet timely alerts on market opportunities - Jammu Links News
Should I hold or sell Vor Biopharma Inc. stock in 2025Achieve breakthrough financial results - jammulinksnews.com
Does Vor Biopharma Inc. stock perform well during market downturnsMaximize your portfolio’s growth potential - Jammu Links News
What markets is Vor Biopharma Inc. expanding into Is DMAC stock a good long term investment option - jammulinksnews.com
What are the latest earnings results for Vor Biopharma Inc.Unlock real-time stock alerts for quick profits - Jammu Links News
How Efficient Is Vor Biopharma Inc. at Controlling Operating CostsDefensive Stock Picks with Upside - metal.it
Published on: 2025-07-27 20:45:01 - jammulinksnews.com
Published on: 2025-07-27 15:05:50 - jammulinksnews.com
How Vor Biopharma Inc. stock performs during market volatilityMarket Ready Callouts - metal.it
Is Vor Biopharma Inc. a good long term investmentOverwhelming profit margins - PrintWeekIndia
Vor Biopharma Inc. Stock Analysis and ForecastMassive profits - PrintWeekIndia
Vor Bio appoints Sandy Mahatme as CFO - MSN
Vor Biopharma Inc. (NASDAQ:VOR) Shares Could Be 21% Below Their Intrinsic Value Estimate - 富途牛牛
Vor Biopharma Inc Stock (VOR) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.10%
0.21%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):